Article

FDA approves treatment for cystinosis

The FDA has approved cysteamine ophthalmic solution (Cystaran, Sigma-Tau Pharmaceuticals) 0.44% for corneal cystine crystal accumulation in patients with cystinosis.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Related Content
(Image credit: AdobeStock/InkInvent) FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy
August 14th 2025

FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy

3 Things You Should Know About the GA Pipeline
August 14th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Q&A: Understanding the influences on molecular confirmation after genetic testing for IRDs
August 14th 2025

Q&A: Understanding the influences on molecular confirmation after genetic testing for IRDs

Patient-Centered Treatment Strategies in the Management of nAMD and DME
August 14th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Lupin and Sandoz sign licensing deal for biosimilar ranibizumab across multiple regions
August 14th 2025

Lupin and Sandoz sign licensing deal for biosimilar ranibizumab across multiple regions

What the eyes reveal: Cardiovascular clues in women—hidden in plain sight
August 14th 2025

What the eyes reveal: Cardiovascular clues in women—hidden in plain sight

© 2025 MJH Life Sciences

All rights reserved.